Zacks.com on MSN1d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to ...
Outsourcing-pharma2d
Pfizer’s HYMPAVZI for Hemophilia A or B receives EU approval
The European Commission has approved Pfizer’s treatment for adults and adolescents with severe hemophilia A or B.
Pharmabiz2d
Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age ...
The Pharma Letter2d
EC approval for Pfizer’s Hympavzi
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. The ...
pharmaphorum3d
Pfizer bags EU okay for haemophilia drug Hympavzi
Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU that can be delivered via an autoinjector device at home.
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
For those looking for great candidates, here are two in the healthcare sector: Merck (NYSE: MRK) and Pfizer (NYSE: PFE). Is ...